Q2 2026

Interim report
January - June

Interim report January - June 2026

A strong quarter

Second quarter

- Revenue increased by 17 per cent to EUR 121.6m (104.3) with organic growth of 12 per cent. Acquisitions contributed with 6 per cent and negative impact from currency movements of -1 per cent.
- Operating profit (EBIT) of EUR 22.3m (14.5)
- EBITA of EUR 28.8m (20.0), including items affecting comparability of EUR -0.9m (-5.3). Adjusted EBITA increased 17 per cent to EUR 29.7m (25.4) corresponding to a margin of 24.5 per cent (24.3)
- Profit for the period of EUR 8.8m (8.6) and earnings per share before and after dilution EUR 0.02 (0.02)
- Cash flow from operating activities of EUR 3.8m (22.2)

First six months

- Revenue increased by 12 per cent to EUR 237.6m (211.8) with organic growth of 10 per cent. Acquisitions contributed with 5 per cent and negative impact from currency movements of -3 per cent.
- Operating profit (EBIT) of EUR 43.5m (30.1)
- EBITA of EUR 56.2m (41.3), including items affecting comparability of EUR -2.7m (-12.3). Adjusted EBITA increased 10 per cent to EUR 58.9m (53.7) corresponding to a margin of 24.8 per cent (25.3)
- Profit for the period of EUR 18.9m (13.3) and earnings per share before and after dilution EUR 0.03 (0.02)
- Cash flow from operating activities of EUR 26.9m (39.3)

Significant events during the second quarter

- The number of shares and votes increased during June as a result of share subscriptions through the exercise of warrants as part of LTI 2023. In total, the number of shares has increased by 1,093,738 ordinary shares and the same number of votes.

Significant events after the second quarter

- No significant events occurred after the end of the second quarter.

Financial key ratios

EURm, unless otherwise stated	Apr-Jun 2026	Apr-Jun 2025	Δ%	Jan-Jun 2026	Jan-Jun 2025	Δ%	Jul-Jun 25/26	Full-year 2025
Revenue	121.6	104.3	*17%*	237.6	211.8	*12%*	450.9	425.0
Organic revenue growth (%)[1]	12%	5%		10%	5%			6%
EBITA	28.8	20.0	*44%*	56.2	41.3	*36%*	105.6	90.7
EBITA margin (%)	23.7%	19.2%	*4.5 pp*	23.7%	19.5%	*4.1 pp*	23.4%	21.3%
Adjusted EBITA[1]	29.7	25.4	*17%*	58.9	53.7	*10%*	110.6	105.3
Adjusted EBITA margin (%)[1]	24.5%	24.3%	*0.1 pp*	24.8%	25.3%	*-0.5 pp*	24.5%	24.8%
Operating profit (EBIT)	22.3	14.5	*54%*	43.5	30.1	*45%*	80.3	66.8
Profit for the period	8.8	8.6		18.9	13.3	*42%*	37.9	32.3
Items affecting comparability[2]	-0.9	-5.3		-2.7	-12.3		-5.0	-14.7
Earnings per share before dilution (EUR)	0.02	0.02		0.03	0.02		0.07	0.06
Earnings per share after dilution (EUR)	0.02	0.02		0.03	0.02		0.07	0.06
Cash flow from operating activities	3.8	22.2	*-83%*	26.9	39.3	*-32%*	93.3	105.7

1 Refer to the section on Alternative performance measures for more information.
2 Refer to Note 3 and the section on Items affecting comparability for more information.

Message from our CEO

A strong quarter

Vimian delivered a strong second quarter with strong revenue and earnings growth, and improved margin. Total revenues grew 17 per cent to EUR 121.6 million with organic growth of 12 per cent, ahead of the overall animal health market.

Adjusted EBITA grew 17 per cent to EUR 29.7 million with strong performance across all four segments. The adjusted EBITA margin reached 24.5 per cent (24.3), mainly driven by improved profitability in the MedTech segment.

Cash from operations was EUR 3.8 million, driven by timing effects with increase in receivables following a strong finish to the quarter, and tax payments.

Specialty Pharma – another strong quarter
Specialty Pharma achieved another strong quarter with 14 per cent organic growth mainly driven by the therapeutic areas Specialty Pharmaceuticals and Specialised Nutrition. In Specialised Nutrition, we completed another successful national sales campaign in US together with one of the leading retailers. A similar campaign took place in the third quarter of 2025, which makes growth vary between quarters although the underlying business trend is solid.

During the quarter we launched 25 new products and opened our new R&D hub in France focused on the development of biological pharmaceuticals for treatment of complex and autoimmune diseases like allergies.

The adjusted EBITA margin remained strong at 30.1 per cent (30.0).

MedTech – return to double-digit growth
MedTech achieved 11 per cent organic growth, with double-digit growth in both the dental and the orthopedics business. As expected, our US orthopedics business returned to growth during spring, on the back of our consistent efforts to strengthen commercial performance. Our focus on education to unlock long-term market growth in both orthopedics and dental remains, and we educated 1,300 veterinarians in the quarter.

The adjusted EBITA margin improved to 25.8 per cent (23.7), driven by the consolidation of acquired businesses in veterinary dental.

Veterinary Services – continued strong growth
Veterinary Services delivered 10 per cent organic growth in the quarter with continued momentum in new member growth and strategic partnerships. The adjusted EBITA margin reached 28.2 per cent (28.7), as expected somewhat lower than previous year due to mix effects from acquisitions and our growth investments in new markets and services.

Diagnostics – focus on companion animal remains
Diagnostics delivered 7 per cent organic growth in the quarter. We continued to work on our organic and inorganic initiatives to strengthen our position in the attractive companion animal diagnostics market. The adjusted EBITA margin declined slightly to 9.0 per cent (9.2), driven by product mix.

Well-positioned following a successful first half year
Summarizing the first half of 2026, I am happy to see that improved execution of our key strategic focus areas has proven successful. The company has a strong financial base, we are growing organically at a pace well above the market and have closed four acquisitions year-to-date in our efforts to create a stronger global group. The global animal health market continues to grow, we are attractively positioned in our select market niches with investments in exciting long-term initiatives and have developed a highly active M&A pipeline.

For the remainder of the year, our focus will be on executing the M&A pipeline, continuing to drive organic growth and build a stronger cross-company culture built on the foundation of our shared purpose – to improve animal health through science and technology for better lives.

Alireza Tajbakhsh
CEO of Vimian Group AB (publ)

Group performance

Second quarter 2026

Revenue
Revenue increased by 17 per cent to EUR 121.6m (104.3). Organic revenue growth was 12 per cent driven by Specialty Pharma and MedTech with 14 per cent and 11 per cent organic growth respectively. Veterinary Services organic growth was 10 per cent. Diagnostics delivered organic growth of 7 per cent.

Acquisitions contributed with 6 per cent and negative impact of -1 per cent from currency movements.

Operating profit
Operating profit (EBIT) amounted to EUR 22.3m (14.5) at a margin of 18.4 per cent (13.9). This includes items affecting comparability of EUR -0.9m (-5.3).

Most items affecting comparability relates to acquisition costs in Veterinary Services and Diagnostics of in total EUR -0.5m. For further information on items affecting comparability, refer to Note 3.

EBITA
EBITA increased by 44 per cent to EUR 28.8m (20.0) at a margin of 23.7 per cent (19.2).

Adjusted EBITA
Adjusted EBITA increased by 17 per cent to EUR 29.7m (25.4) at a margin of 24.5 per cent (24.3).

Financial items
Net financial items amounted to EUR -8.0m (-1.6). This consists of three main parts: (1) financing expenses of EUR -3.1m with an average interest rate of 3.9 per cent during the quarter, partly offset by interest income of EUR 0.2m; (2) a quarterly discounting impact of EUR -1.0m and negative impact of EUR -2.5m from probability adjustments related to contingent considerations; (3) a negative impact of EUR -1.6m from exchange rate effects on the revaluation of debt.

Tax
Income tax expense for the quarter was EUR -5.5m (-4.2) at an effective tax rate of 39 per cent. In the quarter the tax expense as percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses.

Profit for the period
Profit for the period amounted to EUR 8.8m (8.6), negatively impacted by EUR -1.6m from exchange rates included in financial items and by EUR -2.5m from probability adjustment on contingent liabilities. Earnings per share before and after dilution amounted to EUR 0.02 (0.02).

Cash flow
Cash flow from operating activities amounted to EUR 3.8m (22.2). Cash flow from investing activities of EUR -22.9m (-77.6) primarily consisting of acquisitions and earn-out payments. Cash flow from financing activities amounts to EUR 20.5m (65.4).

Net working capital
Net working capital amounted to EUR 114.1m (99,5) per the end of June at 26 (25) per cent of revenue, an increase from EUR 92.8m at the end of March 2026 (21 per cent of revenue). Compared to end of March 2026, net working capital increased by EUR 21.3m. The increase can mainly be explained by payment of accrued income taxes, higher inventory levels and trade receivables.

Quarterly revenue



Quarterly adjusted EBITA



Capital expenditure

Capital expenditure amounted to EUR -4.7m (-3.0). This is split between EUR -1.4m investments in intangible assets (internal R&D, software development and R&D partnerships) and EUR -3.3m investments in property, plant and equipment (the larger investments include leasehold improvements and expansion of premises in MedTech and Speciality Pharma).

The capex of EUR -4.7m accounts for 3.9 per cent of sales, compared to 2.9 per cent for the same period in the previous year. The higher capex as a percentage of sales is due to higher investments in capitalized R&D as well as investments in premises.

Net debt and cash and cash equivalents

At the end of the period, net debt amounted to EUR 273.7m (260,6), up from EUR 258.4m per 31 March 2026. Cash and cash equivalents amounted to EUR 51.6m (67.5) an increase compared to EUR 50.4m at the end of March. External lending of EUR 261.7m (277.5).

Per 30 June, net debt in relation to pro-forma adjusted EBITDA over the past 12-month period was 2.1x, unchanged compared with 31 March 2026.

Central Costs

Central costs amounted to EUR -3.0m (-2.2). Central costs include EUR -0.8m expenses related to the 2024, 2025 and 2026 long term incentive programmes (employee stock options and investment shares). These are non-cash IFRS expenses that will recur at for the duration of the three-year programs.

January to June 2026

Revenue
Revenue increased by 12 per cent to EUR 237.6m (211.8). Organic revenue growth was 10 per cent driven by Specialty Pharma and MedTech with 12 per cent and 9 per cent organic growth respectively. Veterinary Services organic growth was 10 per cent. Diagnostics delivered organic growth of 10 per cent.

Acquisitions contributed with 5 per cent and negative impact of -3 per cent from currency movements.

Operating profit
Operating profit (EBIT) amounted to EUR 43.5m (30.1) at a margin of 18.3 per cent (14.2). This includes items affecting comparability of EUR -2.7m (-12.3).

Most items affecting comparability relates to acquisition costs in MedTech, Veterinary Services and Diagnostics of EUR -1.6m. In MedTech, the litigation costs in the US indemnification dispute amounted to EUR -1.0m. For further information on items affecting comparability, refer to Note 3.

EBITA
EBITA increased by 36 per cent to EUR 56.2m (41.3) at a margin of 23.7 per cent (19.5).

Adjusted EBITA
Adjusted EBITA increased by 10 per cent to EUR 58.9m (53.7) at a margin of 24.8 per cent (25.3).

Financial items
Net financial items amounted to EUR -11.2m (-9.1). This consists of three main parts: (1) financing expenses of EUR -6.3m, partly offset by interest income of EUR 0.3m; (2) a discounting impact of EUR -2.3m and negative impact of EUR -2.3m from probability adjustments related to contingent considerations; (3) a negative impact of EUR -0.7m from exchange rate effects on the revaluation of debt.

Tax
Income tax expense for the period was EUR -10.8m (-7.7) at an effective tax rate of 36 per cent. The tax expense as percentage of pre-tax profit was negatively affected by probability adjustments related to contingent considerations and other non-deductible expenses.

Profit for the period
Profit for the period amounted to EUR 18.9m (13.3), negatively impacted by EUR -0.7m from exchange rates included in financial items and by EUR -2.3m from probability adjustment on contingent liabilities. Earnings per share before and after dilution amounted to EUR 0.03 (0.02).

Cash flow
Cash flow from operating activities amounted to EUR 26.9m (39.3). Cash flow from investing activities of EUR -56.5m (-90.2) primarily consisting of acquisitions and earn-out payments. Cash flow from financing activities amounts to EUR 25.6m (56.2).

Capital expenditure
Capital expenditure amounted to EUR -11.5m (-6.2). This is split between EUR -4.8m investments in intangible assets (internal R&D, software development and R&D partnerships) and EUR -6.7m investments in property, plant and equipment (the larger investments include leasehold improvements and expansion of premises in MedTech and Speciality Pharma).

Central Costs
Central costs amounted to EUR -5.9m (-4.4). Central costs include EUR -1.4m expenses related to the 2024, 2025 and 2026 long term incentive programmes (employee stock options and investment shares). These are non-cash IFRS expenses that will recur at for the duration of the three-year programs.

Segment performance

Second quarter 2026

Vimian operates through four reporting segments: Specialty Pharma, MedTech, Veterinary Services and Diagnostics

Revenue

EURm	Apr-Jun 2026	Apr-Jun 2025	Δ	Jan-Jun 2026	Jan-Jun 2025	Δ	Jul-Jun 25/26	Full-year 2025
Specialty Pharma	51.2	45.3	*13%*	98.7	90.2	*9%*	190.9	182.4
MedTech	43.3	37.1	*17%*	87.2	78.2	*11%*	164.4	155.5
Veterinary Services	19.4	16.2	*20%*	36.9	31.7	*16%*	69.5	64.3
Diagnostics	7.7	5.7	*36%*	14.8	11.7	*27%*	26.1	22.9
Group	**121.6**	**104.3**	***17%***	**237.6**	**211.8**	***12%***	**450.9**	**425.0**

Adjusted EBITA

EURm	Apr-Jun 2026	Apr-Jun 2025	Δ	Jan-Jun 2026	Jan-Jun 2025	Δ	Jul-Jun 25/26	Full-year 2025
Specialty Pharma	15.4	13.6	*13%*	29.8	26.5	*12%*	57.2	53.9
MedTech	11.2	8.8	*27%*	23.1	20.9	*11%*	41.8	39.6
Veterinary Services	5.5	4.6	*18%*	10.3	9.3	*10%*	19.4	18.4
Diagnostics	0.7	0.5	*32%*	1.7	1.4	*22%*	2.5	2.2
Group Functions	-3.0	-2.2	*-39%*	-5.9	-4.4	*33%*	-10.2	-8.8
Group	**29.7**	**25.4**	***17%***	**58.9**	**53.7**	***10%***	**110.6**	**105.3**

Revenue per segment, Q2 2026



Adjusted EBITA per segment, Q2 2026[1]



[1] Adjusted EBITA before central costs.

Segment – Specialty Pharma

EURm	Apr-Jun 2026	Apr-Jun 2025	Δ	Jan-Jun 2026	Jan-Jun 2025	Δ	Jul-Jun 25/26	Full-year 2025
Revenue	51.2	45.3	*13%*	98.7	90.2	*9%*	190.9	182.4
Organic revenue growth (%)	14%	6%	*8 pp*	12%	8%	*5 pp*		8%
EBITA	15.1	13.5	*12%*	29.5	26.0	*14%*	56.8	53.3
EBITA margin (%)	29.6%	29.9%	*-0.3 pp*	29.9%	28.8%	*1.1 pp*	29.8%	29.2%
Adjusted EBITA	15.4	13.6	*13%*	29.8	26.5	*12%*	57.2	53.9
Adjusted EBITA margin (%)	30.1%	30.0%	*0.1 pp*	30.2%	29.4%	*0.8 pp*	30.0%	29.6%

Revenue
Revenue in the second quarter grew 13 per cent to EUR 51.2 million (45.3). Organic growth was 14 per cent, with no contribution from acquisitions and -1 per cent negative impact from currency movements.

Growth across all therapeutic areas with strongest contribution from Specialised Nutrition and Specialty Pharmaceuticals. In Specialised Nutrition, a national sales campaign in US supported strong revenue growth. Adjusting for the impact from this campaign, organic growth in Specialty Pharma was 9 per cent. A similar campaign was carried out in the third quarter of last year.

During the second quarter 25 new products were launched.

Net revenue during January to June grew 9 per cent to EUR 98.7 million (90.2). Organic growth of 12 per cent, contribution from acquisitions 0 per cent and -3 per cent negative impact from currency movements.

Adjusted EBITA
Adjusted EBITA in the second quarter increased by 13 per cent to EUR 15.4 million (13.6) at a margin of 30.1 per cent (30.0).

Adjusted EBITA for the period January to June increased by 12 per cent to EUR 29.8 million (26.5) at a margin of 30.2 per cent (29.4).

Quarterly revenue Specialty Pharma



Quarterly adjusted EBITA Specialty Pharma



Segment – MedTech

EURm	Apr-Jun 2026	Apr-Jun 2025	Δ	Jan-Jun 2026	Jan-Jun 2025	Δ	Jul-Jun 25/26	Full-year 2025
Revenue	43.3	37.1	*17%*	87.2	78.2	*11%*	164.4	155.5
Organic revenue growth (%)	11%	-4%	*15 pp*	9%	- 6%	*14 pp*		- 1%
EBITA	10.7	5.6	*92%*	21.5	11.7	*83%*	39.6	29.9
EBITA margin (%)	24.8%	15.1%	*9.7 pp*	24.6%	15.0%	*9.6 pp*	24.1%	19.2%
Adjusted EBITA	11.2	8.8	*27%*	23.1	20.9	*11%*	41.8	39.6
Adjusted EBITA margin (%)	25.8%	23.7%	*2.1 pp*	26.5%	26.7%	*-0.2 pp*	25.4%	25.5%

Revenue
Revenue in the second quarter increased 17 per cent to EUR 43.3 million (37.1). Organic growth of 11 per cent, with 7 per cent contribution from acquisitions in veterinary dental and -1 per cent negative impact from currency movements.

Organic growth was driven by continued double-digit growth in the dental business as well as in the orthopedics business in Europe and Asia-Pacific. In North America, the orthopedics business delivered low single-digit organic growth in the quarter.

Net revenue during January to June grew 11 per cent to EUR 87.2 million (78.2). Organic growth of 9 per cent, contribution from acquisitions 7 per cent and -4 per cent negative impact from currency movements.

Adjusted EBITA
Adjusted EBITA in the second quarter increased by 27% to EUR 11.2 million (8.8) at a margin of 25.8 per cent (23.7). The margin improvement was driven by positive mix impact from bolt-on acquisitions in veterinary dental.

Adjusted EBITA for the period January to June increased by 11 per cent to EUR 23.1 million (20.9) at a margin of 26.5 per cent (26.7).

Quarterly revenue MedTech



Quarterly adjusted EBITA MedTech



Segment – Veterinary Services

EURm	Apr-Jun 2026	Apr-Jun 2025	Δ	Jan-Jun 2026	Jan-Jun 2025	Δ	Jul-Jun 25/26	Full-year 2025
Revenue	19.4	16.2	*20%*	36.9	31.7	*16%*	69.5	64.3
Organic revenue growth (%)	10%	12%	*-2 pp*	10%	12%	*-2 pp*		11%
EBITA	4.3	4.6	*-8%*	8.6	9.2	*-7%*	17.4	18.0
EBITA margin (%)	22.1%	28.7%	*-6.6 pp*	23.3%	29.0%	*-5.7 pp*	25.1%	28.1%
Adjusted EBITA	5.5	4.6	*18%*	10.3	9.3	*10%*	19.4	18.4
Adjusted EBITA margin (%)	28.2%	28.7%	*-0.5 pp*	27.9%	29.5%	*-1.6 pp*	27.9%	28.6%

Revenue
Revenue for the second quarter grew 20 per cent to EUR 19.4 million (16.2). Organic growth of 10 per cent, with 11 per cent contribution from acquisitions and -1 per cent from currency movements.

The member base continued to increase reaching 11,900 members by the end of the second quarter. The combination of continued growth in new members and an increased share of wallet continued to support the double-digit organic growth.

Co-owned clinics accounted for approximately a third of segment revenue and delivered low single-digit growth in the quarter.

Net revenue during January to June grew 16 per cent to EUR 36.9 million (31.7). Organic growth of 10 per cent, contribution from acquisitions 7 per cent and -1 per cent negative impact from currency movements.

Adjusted EBITA
Adjusted EBITA for the second quarter increased 18 per cent to EUR 5.5 million (4.6) at a margin of 28.2 per cent (28.7).

The year-over-year margin was mainly impacted by mix effects from acquisitions as well as investments in new markets and services.

Adjusted EBITA for the period January to June increased by 10 per cent to EUR 10.3 million (9.3) at a margin of 27.9 per cent (29.5).

Quarterly revenue Veterinary Services



Quarterly adjusted EBITA Veterinary Services



Segment – Diagnostics

EURm	Apr-Jun 2026	Apr-Jun 2025	Δ	Jan-Jun 2026	Jan-Jun 2025	Δ	Jul-Jun 25/26	Full-year 2025
Revenue	7.7	5.7	*36%*	14.8	11.7	*27%*	26.1	22.9
Organic revenue growth (%)	7%	18%	*-11 pp*	10%	17%	*-7 pp*		10%
EBITA	0.4	0.5	*-6%*	1.3	1.3	*2%*	1.5	1.4
EBITA margin (%)	5.7%	8.2%	*-2.5 pp*	8.7%	10.9%	*-2.2 pp*	5.6%	6.3%
Adjusted EBITA	0.7	0.5	*32%*	1.7	1.4	*22%*	2.5	2.2
Adjusted EBITA margin (%)	9.0%	9.2%	*-0.3 pp*	11.3%	11.8%	*-0.5 pp*	9.5%	9.5%

Revenue
Revenue in the second quarter increased by 36 per cent to EUR 7.7 million (5.7). Organic growth of 7 per cent, with 29 per cent contribution from acquisitions and no impact from currency movements.

Organic growth supported by positive development across the business. The companion animal diagnostics business I-Vet that was consolidated on 2 March this year delivered strong growth in the quarter.

Net revenue during January to June grew 27 per cent to EUR 14.8 million (11.7). Organic growth of 10 per cent, contribution from acquisitions 19 per cent and -1 per cent negative impact from currency movements

Adjusted EBITA
Adjusted EBITA for the second quarter increased by 32 per cent to EUR 0.7 million (0.5) at a margin of 9.0 per cent (9.2).

The lower margin reflects product mix with higher levels of extraction sales.

Adjusted EBITA for the period January to June increased by 22 per cent to EUR 1.7 million (1.4) at a margin of 11.3 per cent (11.8).

Quarterly revenue Diagnostics



Quarterly adjusted EBITA Diagnostics



Declaration of the Board of Directors and Chief Executive Officer

The Board of Directors and Chief Executive Officer declare that the interim report provides a true and fair view of the development of the Group's and parent company's business, its financial position and results, and describes significant risks and uncertainties faced by the parent company and the companies included in the Group.

Stockholm, 17 July 2026

Magnus Welander
Chairman

Gabriel Fitzgerald

Pia Marions

Petra Rumpf

Theodor Bonnier

Alireza Tajbakhsh
Group CEO

This report has not been reviewed by the company's auditors.

Prior to publication this information constituted inside information that Vimian Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the above contact persons, at 07:45 am CEST on 17 July 2026.

Webcast conference call on 17 July 2026: In connection with the interim report, Vimian will hold a webcast conference call in English at 09:00 am CEST. Vimian will be represented by CEO Alireza Tajbakhsh and CFO Carl-Johan Zetterberg Boudrie, who will present the interim report and answer questions. Information regarding telephone numbers is available at www.vimian.com/investors. The presentation will be available at www.vimian.com/investors after publication of the interim report. The webcast will be available at the same address after the live broadcast.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS

EURm unless otherwise stated	Note	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full-year 2025
Revenue from contracts with customers	3, 4	121.6	104.3	237.6	211.8	425.0
Revenue		**121.6**	**104.3**	**237.6**	**211.8**	**425.0**
Other operating income	10	1.3	1.0	2.4	1.7	3.3
Raw material and merchandise		-38.4	-32.2	-73.2	-64.8	-132.2
Other external expenses	10	-19.8	-21.7	-41.1	-45.6	-81.4
Personnel expenses		-30.5	-27.5	-59.6	-54.0	-108.2
Depreciation and amortisation		-10.5	-8.9	-20.7	-17.9	-37.9
Other operating expenses		-1.3	-0.5	-1.9	-0.9	-1.8
Operating profit		**22.3**	**14.5**	**43.5**	**30.1**	**66.8**
Net financial items		-8.0	-1.6	-11.2	-9.1	-20.6
Share of profit of an associate		-0.1	-	-2.5	-	-0.3
Profit before tax		**14.2**	**12.9**	**29.7**	**21.0**	**45.9**
Income tax expense		-5.5	-4.2	-10.8	-7.7	-13.5
Profit for the period		**8.8**	**8.6**	**18.9**	**13.3**	**32.3**
Profit for the period attributable to:						
Equity holders of the parent		8.4	8.3	18.2	12.7	31.3
Non-controlling interests		0.4	0.3	0.7	0.7	1.1
Earnings per share, before dilution (EUR)		0.02	0.02	0.03	0.02	0.06
Earnings per share, after dilution (EUR)		0.02	0.02	0.03	0.02	0.06
Average number of shares, before dilution (Thousands)		529,323	523,921	529,293	523,906	525,701
Average number of shares, after dilution (Thousands)		529,323	524,202	529,293	524,187	525,701
Number of shares at the end of the period (Thousands)		530,356	526,615	530,356	526,615	529,263

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

EURm	Note	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full-year 2025
Profit for the period		**8.8**	**8.6**	**18.9**	**13.3**	**32.3**
Other comprehensive income						
Items that may be reclassified to profit or loss:						
Exchange differences on translation of foreign operations		-1.2	-26.6	8.6	-38.0	-41.5
Remeasurement of interest derivatives to fair value		4.5	-	5.2	-	-
Items that will not be reclassified to profit or loss:						
Remeasurement of defined benefit plans		-0.0	0.0	0.1	0.1	-0.0
Other comprehensive income for the period, net of tax		**3.3**	**-26.6**	**13.9**	**-37.9**	**-41.5**
Total comprehensive income for the period, net of tax		**12.0**	**-17.9**	**32.8**	**-24.6**	**-9.2**
Total comprehensive income attributable to:						
Equity holders of the parent		12.1	-17.1	32.1	-23.5	-8.7
Non-controlling interests		-0.1	-0.8	0.6	-1.1	-0.4

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

EURm	Note	30 Jun 2026	30 Jun 2025	31 Dec 2025
Non-current assets				
Goodwill		624.3	617.8	590.1
Intangible assets		244.6	208.4	238.9
Property, plant and equipment		38.5	29.2	31.6
Right-of-use assets		16.6	16.0	14.8
Investment in associates		13.0	9.2	14.1
Non-current financial assets		1.0	24.8	1.5
Deferred tax assets		5.7	1.5	5.2
Total non-current assets		**943.6**	**906.9**	**896.3**
Current assets				
Inventories		93.4	80.0	80.1
Trade receivables		71.5	58.9	57.3
Current tax receivables		3.1	1.3	1.2
Other receivables		7.8	8.2	6.7
Prepaid expenses and accrued income		14.4	13.9	13.2
Cash and cash equivalents		51.6	67.5	55.0
Total current assets		**241.9**	**229.9**	**213.5**
TOTAL ASSETS		**1,185.4**	**1,136.9**	**1,109.8**

EURm	Note	30 Jun 2026	30 Jun 2025	31 Dec 2025
Equity				
Share capital		0.1	0.1	0.1
Other contributed capital		630.2	625.1	626.3
Reserves		-22.5	-32.7	-36.5
Retained earnings including this period's profit		127.2	90.4	109.0
Total equity attributable to equity holders of the parent		**735.0**	**682.9**	**698.9**
Non-controlling interests		10.5	9.2	9.9
Total equity		**745.7**	**692.2**	**708.8**
Non-current liabilities				
Bonds		150.0	150.0	150.0
Liabilities to credit institutions		111.7	127.5	73.3
Lease liabilities		11.9	11.8	10.3
Deferred tax liabilities		35.8	27.4	35.5
Other non-current liabilities	5	29.3	32.3	20.9
Non-current provisions		1.5	1.6	1.6
Total non-current liabilities		**340.3**	**350.6**	**291.6**
Current liabilities				
Lease liabilities		5.2	4.7	5.1
Trade payables		27.8	22.8	20.1
Current tax liabilities		8.5	10.4	10.3
Other current liabilities		34.4	34.6	53.9
Accrued expenses and prepaid income		21.5	21.3	19.2
Provisions		2.0	0.3	0.8
Total current liabilities		**99.4**	**94.2**	**109.4**
TOTAL EQUITY AND LIABILITIES		**1,185.4**	**1,136.9**	**1,109.8**

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

EURm	Share capital	Other contributed capital	Translation reserve	Retained earnings including this period's profit	Total equity attributable to equity holders of the parent	Non-controlling interests	Total equity
	Equity attributable to equity holders of the parent						
Opening balance 1 January 2025	**0.1**	**614.9**	**3.5**	**81.5**	**699.9**	**6.6**	**706.5**
Profit for the period				12.7	12.7	0.7	13.3
Other comprehensive income			-36.2		-36.2	-1.7	-37.9
Total comprehensive income	**-**	**-**	**-36.2**	**12.7**	**-23.5**	**-1.1**	**-24.6**
Transactions with owners							
Share issue		10.3			10.3		10.3
Transactions with non-controlling interests				-3.7	-3.7	3.7	-
Total	**-**	**10.3**	**-**	**-3.7**	**6.5**	**3.7**	**10.3**
Closing balance 30 June 2025	**0.1**	**625.1**	**-32.7**	**90.5**	**682.9**	**9.2**	**692.2**
Opening balance 1 January 2026	**0.1**	**626.3**	**-36.5**	**109.0**	**698.9**	**9.9**	**708.9**
Profit for the period				18.2	18.2	0.7	18.9
Other comprehensive income			14.0		14.0	-0.0	13.9
Total comprehensive income	**-**	**-**	**14.0**	**18.2**	**32.1**	**0.6**	**32.8**
Transactions with owners							
Share issue	0.0	3.0			3.0		3.0
Transaction costs		-0.0			-0.0		-0.0
Warrant program		1.0			1.0		1.0
Total	**0.0**	**3.9**	**-**	**-**	**3.9**	**-**	**3.9**
Closing balance 30 June 2026	**0.1**	**630.2**	**-22.5**	**127.2**	**735.0**	**10.5**	**745.7**

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

EURm	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full-year 2025
Operating activities					
Operating profit	22.3	14.5	43.5	30.1	66.8
Adjustments for non-cash items	12.4	20.5	22.1	31.7	54.4
Interest received	0.6	0.5	0.7	1.0	1.2
Interest paid	-2.7	-2.6	-6.5	-6.0	-15.7
Paid income tax	-13.5	-2.9	-17.4	-4.3	-17.4
Cash flow from operating activities before change in working capital	**19.2**	**30.0**	**42.5**	**52.4**	**89.3**
Change in inventories	-5.2	-5.3	-11.7	-6.5	-6.7
Change in operating receivables	-10.0	-1.2	-15.7	-9.4	20.9
Change in operating liabilities	-0.2	-1.4	11.8	2.8	2.3
Cash flow from operating activities	**3.8**	**22.2**	**26.9**	**39.3**	**105.7**
Investing activities					
Acquisition of a subsidiary, net of cash acquired, Note 5 and 6	-19.4	-76.0	-46.3	-85.9	-92.2
Investments in associates	-	-0.0	-	-0.0	-5.1
Proceeds from sale of associates	-	-	-	-	0.1
Investments in intangible assets	-1.4	-1.1	-4.8	-2.4	-6.0
Proceeds from sale of intangible assets	1.1		1.1		
Investments in property, plant and equipment	-3.3	-2.0	-6.7	-3.8	-9.1
Proceeds from sale of property, plant and equipment	0.0	-	0.0	0.0	0.1
Investments in financial assets	0.0	1.4	0.2	1.9	-0.5
Cash flow from investing activities	**-22.9**	**-77.6**	**-56.5**	**-90.2**	**-112.8**
Financing activities					
New share issue	3.4	10.3	3.4	10.3	10.5
Share issue - Transaction costs	-	0.0	-	0.0	-0.1
Proceeds from borrowings	28.3	271.4	42.4	272.7	277.8
Repayment of borrowings	-9.7	-215.1	-17.4	-224.4	-284.1
Payment of lease liabilities	-1.4	-1.2	-2.8	-2.4	-4.9
Transactions with non-controlling interests	-	-	-	-	-0.4
Cash flow from financing activities	**20.5**	**65.4**	**25.6**	**56.2**	**-1.2**
Cash flow for the period	**1.4**	**10.0**	**-4.1**	**5.3**	**-8.3**
Cash and cash equivalents at beginning of the period	50.4	60.1	55.0	64.8	64.8
Exchange-rate difference in cash and cash equivalents	0.7	-2.6	0.7	-2.6	-1.5
Cash and cash equivalents at end of the period	**51.6**	**67.5**	**51.6**	**67.5**	**55.0**

CONDENSED PARENT COMPANY INCOME STATEMENT AND BALANCE SHEET

SEKm	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Full-year 2025
Revenue	21.6	11.7	45.5	24.4	61.0
Other operating income	0.0	0.0	0.0	0.0	0.0
Total operating income	**21.6**	**11.7**	**45.5**	**24.4**	**61.0**
Other external expenses	-9.7	-12.8	-22.3	-25.5	-48.9
Personnel expenses	-0.5	-32.2	-16.5	-49.8	-75.7
Depreciation and amortisation	-0.8	-0.7	-1.5	-1.4	-2.9
Other operating expenses	0.9	-0.5	-0.2	-1.7	-2.1
Operating profit	**11.6**	**-34.6**	**5.0**	**-54.0**	**-68.6**
Group contributions	0.0	0.0	0.0	0.0	285.4
Net financial items[1]	112.6	54.9	237.7	-169.8	-212.4
Profit before tax	**124.2**	**20.4**	**242.7**	**-223.8**	**4.5**
Income tax expense	0.0	0.0	0.0	0.0	24.4
Profit for the period	**124.2**	**20.4**	**242.7**	**-223.8**	**28.9**

[1] Net Financial items for the year includes interest income of SEK 150.2m (170.4), dividend from subsidiary 0.0 (95.0), interest expenses (including bank fees) of SEK -69.8 (-81.8) and exchange rate differences of SEK 157.3 (-353.5).

SEKm	30 Jun 2026	30 Jun 2025	31 Dec 2025
ASSETS			
Own work capitalised	8.9	11.7	10.3
Other intangible assets	0.9	-	-
Property, plant and equipment	0.1	0.2	0.2
Shares in subsidiaries	6,581.7	6,242.1	6,254.3
Recievables from group companies	7,254.7	7,253.3	6,840.1
Deferred tax asset	40.6	-	40.6
Other non current assets	7.4	-	-
Total non-current assets	13,894.2	13,507.3	13,145.5
Recievables from group companies	318.7	280.1	399.2
Other receivables	9.4	8.9	2.5
Prepaid expenses and accrued income	3.5	35.6	82.9
Cash and cash equivalents	-	-	-
Total current assets	331.6	324.6	484.6
TOTAL ASSETS	14,225.8	13,831.9	13,630.1
EQUITY AND LIABILITIES			
Share capital	0.9	0.9	0.9
Development fund	9.0	13.1	10.3
Fair value fund	7.4	-	2.5
Share premium	8,420.9	8,379.4	8,381.1
Retained earnings	2,112.5	2,064.4	2,084.2
Profit for the period	242.7	-223.8	28.9
Total equity	10,793.3	10,234.0	10,507.8
Bonds	1,651.8	1,607.0	1,607.0
Liabilities to credit institutions	1,226.6	1,481.7	781.7
Total non-current liabilities	2,878.4	3,088.7	2,388.7
Payables to Group companies	516.9	462.2	680.7
Trade payables	2.1	2.3	6.7
Other current liabilities	7.8	-0.4	23.8
Current income tax liabilities	0.6	0.4	0.4
Accrued expenses and prepaid income	26.7	44.8	22.0
Total current liabilities	554.1	509.2	733.6
TOTAL EQUITY AND LIABILITIES	14,225.8	13,831.9	13,630.1

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Significant accounting policies

The interim condensed consolidated financial statements comprise of the Swedish parent company Vimian Group AB (publ), with corporate identity number 559234-8923, and its subsidiaries. The Group's primary operations are offering products and services in animal health for domestic pets and livestock around the world. The Group offers goods and services in medicine, diagnostics and medtech as well as services and advice for veterinary professionals. The Parent Company is a limited liability company with its registered office in Stockholm, Sweden. The address of the head office is Riddargatan 19, 114 57 Stockholm.

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and interpretations issued by the IFRS Interpretations Committee (IFRS IC) as adopted by the European Union (EU) and RFR1.

The Group's interim report is prepared in accordance with IAS 34 Interim financial reporting and applicable parts of the Swedish Annual Accounts Act (1995:1554). The interim report of the parent company is prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim financial reporting and Recommendation RFR 2 Accounting for Legal Entities. The Group and Parent Company have applied the same accounting principles, basis of calculation, and assumptions as those applied in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025.

For a complete description of the Group's and Parent Company's applied accounting principles, see note 1 of the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025. Disclosures according to IAS 34 are presented in the financial statements as well as corresponding notes on page 13-25, which are an integrated part of the interim condensed consolidated financial statements. All amounts are presented in millions of Euro ("MEUR"), unless otherwise indicated.

Note 2. Key estimates and assumptions

In preparing the interim financial statements, corporate management and the Board of Directors must make certain assessments and assumptions that impact the carrying amount of asset and liability items and revenue and expense items, as well as other information provided. The actual outcome may then differ from these assessments if other conditions arise. The key estimates and assumptions correspond to the ones described in the Consolidated financial statements of Vimian Group AB as of and for the financial year ended 31 December 2025.

Significant estimates during the financial year 2026 concerns the value of the non-current receivable related to the US patent litigation. On 4 April 2023, Vimian's subsidiary Veterinary Orthopedic Implants LLC ("VOI") reached a settlement agreement with DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. resolving the patent dispute between the parties. Under the terms of the agreement, Vimian paid USD 70 million during the second quarter of 2023.

In the indemnification dispute with the VOI sellers, VOI entered into settlement agreements with three of the four sellers in 2024. Each of the three sellers agreed to compensate Vimian for their entire pro rata shares of the USD 70 million settlement payment to DePuy Synthes. The total value of the three settlements amounts to approximately USD 32 million of which approximately USD 9 million has been contributed by means of dismissal of the contingent closing note from the acquisition of VOI.

On 29 August 2025, the Superior Court of Delaware awarded Vimian USD 40.2 million in damages in the indemnification dispute with the largest seller of VOI. On 1 October the court confirmed the decision from 29 August and also awarded Vimian prejudgement interest of USD 8.6 million. Together with the previously reached settlements with the other sellers, this means that Vimian is entitled to compensation exceeding the USD 70 million settlement paid by Vimian to DePuy Synthes. The largest seller has appealed the court decision. The Supreme Court trial took place in Q2 in Dover, Delaware. Judgment is expected no later than September.

During Q4 2025, the largest seller paid USD 31.9 million. The remaining debt from the largest seller amounts to USD 6.2 million. The payments received exceed the reported receivables on the seller by EUR 2.9 million. Vimian has not reported a provision for the on-going litigation and has also considered the remaining receivable on the seller as doubtful and therefore has not recorded any value in the financial statements.

Note 3. Operating segments

mEUR Apr-Jun 2026	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	51.2	43.3	7.7	19.4	121.6	-	-	121.6
Revenue from internal customers	0.0	0.0	-	0.1	0.1	-0.0	-0.1	-
Total revenue	**51.2**	**43.3**	**7.7**	**19.4**	**121.7**	**-0.0**	**-0.1**	**121.6**
Adjusted EBITA	**15.4**	**11.2**	**0.7**	**5.5**	**32.7**	**-3.0**	**-**	**29.7**
Items affecting comparability	-0.3	-0.5	-0.3	-1.2	-2.2	1.3	-	-0.9
EBITA	**15.1**	**10.7**	**0.4**	**4.3**	**30.6**	**-1.7**	**-**	**28.8**
Amortisation of acquisition-related intangible assets	-3.1	-2.2	-0.3	-0.8	-6.5	-	-	-6.5
Net financial items	-5.6	-4.6	-0.4	-4.0	-14.7	6.7	-	-8.0
Share of profit of an associate and joint venture	-	-	-0.1	-	-0.1	-	-	-0.1
Profit before tax	**6.4**	**3.9**	**-0.4**	**-0.6**	**9.3**	**4.9**	**-**	**14.2**
Specification of items affecting comparability								
Acquisition-related costs	-0.0	0.0	0.2	0.3	0.5	-	-	0.5
Systems update	-	-	-	-	-	-	-	-
Restructuring costs	0.0	0.0	0.0	0.1	0.1	-	-	0.1
IPO and financing related costs	-	-	-	-	-	-	-	-
Other[1]	0.3	0.4	0.1	0.9	1.6	-1.3	-	0.4
Total items affecting comparability	**0.3**	**0.5**	**0.3**	**1.2**	**2.2**	**-1.3**	**-**	**0.9**
Other disclosures								
Investments	3.5	1.1	-0.5	0.5	4.7	0.1	-	4.7
Total assets	534.4	466.7	84.5	192.7	1,278.3	761.2	-854.0	1,185.4
Total liabilities	351.5	352.1	49.5	166.1	919.3	374.5	-854.0	439.7

[1] In Other the segments report paid compensation to the participants in the LTI 2022 programme. The cost is netted to the provision reported by Group functions in Q2-2025.

mEUR Apr-Jun 2025	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	45.3	37.1	5.7	16.2	104.3	-	-	104.3
Revenue from internal customers	0.0	0.0	-	0.0	0.1	-	-0.1	-
Total revenue	**45.3**	**37.1**	**5.7**	**16.2**	**104.3**	**-**	**-0.1**	**104.3**
Adjusted EBITA	**13.6**	**8.8**	**0.5**	**4.6**	**27.5**	**-2.2**	**-**	**25.4**
Items affecting comparability	-0.0	-3.2	-0.1	0.0	-3.3	-2.1	-	-5.3
EBITA	**13.5**	**5.6**	**0.5**	**4.6**	**24.3**	**-4.2**	**-**	**20.0**
Amortisation of acquisition-related intangible assets	-3.1	-1.6	-0.2	-0.7	-5.6	-	-	-5.6
Net financial items	1.9	-6.2	0.3	-1.9	-5.9	8.3	-4.0	-1.6
Share of profit of an associate and joint venture	-	-	-	-	-	-	-	-
Profit before tax	**12.4**	**-2.2**	**0.5**	**2.0**	**12.8**	**4.1**	**-4.0**	**12.9**
Specification of items affecting comparability								
Acquisition-related costs[1]	0.0	0.6	0.1	-0.0	0.7	-	-	0.7
Systems update	-	0.4	-	0.0	0.4	-	-	0.4
Restructuring costs	-0.0	0.0	-	-	0.0	-	-	0.0
IPO and financing related costs	-	-	-	-	-	0.3	-	0.3
Other[2]	0.0	2.1	-	-	2.1	1.8	-	3.9
Total items affecting comparability	**0.0**	**3.2**	**0.1**	**-0.0**	**3.3**	**2.1**	**-**	**5.3**
Other disclosures								
Investments	1.6	0.4	0.4	0.8	3.0	-	-	3.0
Total assets	517.0	465.3	52.5	162.4	1,197.3	727.4	-787.8	1,136.9
Total liabilities	348.3	347.8	33.9	132.9	862.9	369.7	-787.8	444.7

[1] In MedTech, the majority of the acquisition related costs relate to the acquisitions of AllAccem and Dental Focus, closed in Q2-2025.
[2] Main items in other are legal fees related to the US indemnification dispute and provision for compensation to participants in the LTI 2022 programme.

mEUR Jan-Jun 2026	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	98.7	87.2	14.8	36.9	237.6	-	-	237.6
Revenue from internal customers	0.0	0.0	-	0.1	0.1	-	-0.1	-
Total revenue	**98.7**	**87.2**	**14.8**	**37.0**	**237.8**	**-**	**-0.1**	**237.6**
Adjusted EBITA	**29.8**	**23.1**	**1.7**	**10.3**	**64.8**	**-5.9**	**0.0**	**58.9**
Items affecting comparability	-0.3	-1.6	-0.4	-1.7	-4.0	1.3	-	-2.7
EBITA	**29.5**	**21.5**	**1.3**	**8.6**	**60.9**	**-4.6**	**0.0**	**56.2**
Amortisation of acquisition-related intangible assets	-6.2	-4.4	-0.6	-1.6	-12.7	-	-	-12.7
Net financial items	-8.2	-6.8	-0.1	-6.1	-21.2	10.0	-	-11.3
Share of profit of an associate and joint venture	-	-	-2.5	-	-2.5	-	-	-2.5
Profit before tax	**15.2**	**10.2**	**-1.9**	**0.9**	**24.4**	**5.3**	**-0.0**	**29.7**
Specification of items affecting comparability								
Acquisition-related costs	0.0	0.5	0.3	0.8	1.6	-	-	1.6
Systems update	-	-	-	-	-	-	-	-
Restructuring costs	0.0	0.0	0.0	0.1	0.1	-	-	0.1
IPO and financing related costs	-	-	-	-	-	-	-	-
Other[1]	0.3	1.1	0.1	0.9	2.3	-1.3	-	1.0
Total items affecting comparability	**0.3**	**1.6**	**0.4**	**1.7**	**4.0**	**-1.3**	**-**	**2.7**
Other disclosures								
Investments	6.3	2.7	1.4	0.9	11.4	0.1	-	11.5
Total assets	534.4	466.7	84.5	192.7	1,278.3	761.2	-854.0	1,185.4
Total liabilities	351.5	352.1	49.5	166.1	919.3	374.5	-854.0	439.7

[1] In Other the segments report paid compensation to the participants in the LTI 2022 programme. The cost is netted to the provision reported by Group functions in Q2-2025.

EURm Jan-Jun 2025	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Total segments	Group functions	Eliminations	Group total
Revenue								
Revenue from external customers	90.2	78.2	11.7	31.7	211.8	-	-	211.8
Revenue from internal customers	0.0	0.0	-	0.1	0.2	-	-0.2	-
Total revenue	**90.2**	**78.2**	**11.7**	**31.8**	**211.9**	**-**	**-0.2**	**211.8**
Adjusted EBITA	**26.5**	**20.9**	**1.4**	**9.3**	**58.1**	**-4.4**	**-**	**53.7**
Items affecting comparability	-0.5	-9.1	-0.1	-0.1	-9.9	-2.4	-	-12.3
EBITA	**26.0**	**11.7**	**1.3**	**9.2**	**48.2**	**-6.9**	**-**	**41.3**
Amortisation of acquisition-related intangible assets	-6.2	-3.2	-0.4	-1.4	-11.3	-	-	-11.3
Net financial items	-3.4	-9.0	-0.2	-0.7	-13.3	8.3	-4.0	-9.1
Share of profit of an associate and joint venture	-	-	-	-	-	-	-	-
Profit before tax	**16.4**	**-0.5**	**0.6**	**7.1**	**23.6**	**1.4**	**-4.0**	**21.0**
Specification of items affecting comparability								
Acquisition-related costs[1]	0.2	1.8	0.1	0.1	2.3	-	-	2.3
Systems update	-	0.5	-	0.0	0.5	-	-	0.5
Restructuring costs	0.3	0.0	-	-	0.3	-	-	0.3
IPO and financing related costs	-	-	-	-	-	0.6	-	0.6
Other[2]	0.0	6.8	-	-	6.8	1.8	-	8.6
Total items affecting comparability	**0.5**	**9.1**	**0.1**	**0.1**	**9.9**	**2.4**	**-**	**12.3**
Other disclosures								
Investments	2.8	1.3	0.7	1.5	6.2	-	-	6.2
Total assets	517.0	465.3	52.5	162.4	1,197.3	727.4	-787.8	1,136.9
Total liabilities	348.3	347.8	33.9	132.9	862.9	369.7	-787.8	444.7

[1] In Medtech the majority of the acquisition related costs relate to the acquisitions of AllAccem and Dental Focus, closed in Q2-2025.
[2] Main items in other are legal fees related to the US indemnification dispute and provision for compensation to participants in the LIT 2022 programme

Note 4. Revenue from contracts with customers

EURm Apr-Jun 2026	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Geographic region					
Europe	27.1	13.5	5.2	15.1	61.0
North America	20.4	21.5	1.1	3.5	46.5
Rest of the World	3.6	8.3	1.4	0.8	14.1
Revenue from contracts with customers	**51.2**	**43.3**	**7.7**	**19.4**	**121.6**
Whereof from products	88%	98%	98%	5%	79%
Whereof from services	12%	2%	2%	95%	21%

EURm Apr-Jun 2025	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Geographic region					
Europe	25.8	12.0	3.5	12.6	53.9
North America	16.1	18.5	1.0	2.7	38.3
Rest of the World	3.3	7.3	1.2	0.9	12.7
Revenue from contracts with customers	**45.3**	**37.8**	**5.7**	**16.2**	**104.9**
Whereof from products	86%	99%	98%	4%	79%
Whereof from services	14%	1%	2%	96%	21%

EURm Jan-Jun 2026	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Geographic region					
Europe	**54.1**	26.9	9.6	28.5	119.1
North America	37.7	44.8	2.6	6.5	91.6
Rest of the World	6.8	15.5	2.7	1.9	26.9
Revenue from contracts with customers	**98.7**	**87.2**	**14.8**	**36.9**	**237.6**
Whereof from products	88%	98%	97%	5%	79%
Whereof from services	13%	2%	3%	95%	21%

EURm Jan-Jun 2025 Geographic region	Specialty Pharma	MedTech	Diagnostics	Veterinary Services	Group total
Europe	50.9	24.6	7.1	25.1	107.7
North America	32.9	41.1	2.0	5.0	81.0
Rest of the World	6.4	13.2	2.5	1.6	23.7
Revenue from contracts with customers	**90.2**	**78.9**	**11.7**	**31.7**	**212.4**
Whereof from products	87%	99%	97%	5%	79%
Whereof from services	14%	1%	3%	95%	21%

The group has significant exposure to the US, 37 per cent (34) and the UK, 12 per cent (14) markets. All other markets individually represent less than 10 per cent of net revenue. Net revenue from external customers in Sweden amounted to EUR 4.4m (4.6) during the second quarter 2026. No individual customer accounts for more than 10 per cent of Group net revenue.

Note 5. Financial instruments

The carrying amount of the Group's financial instruments measured at fair value regards contingent considerations (see below). The carrying amount of other financial assets and liabilities is deemed to be a good approximation of the fair value.

Contingent consideration

In some of the Group's business combinations, part of the purchase price has been in the form of contingent consideration. The contingent considerations depend on the future earnings or sales of the acquired companies.

The contingent considerations will be settled in cash. The contingent considerations are included in the following line items in the statement of financial position for 30 June 2026: other non-current liabilities EUR 26.0 million (27.9) and other current liabilities EUR 17.0 million (15.2). The contingent considerations are measured at fair value by discounting the expected cash flows by a risk adjusted discount rate. The contingent considerations are classified as level 3 in the fair value hierarchy.

The contingent considerations consist of earn-out agreements in business combinations. The earn-out hurdles are typically linked to sales or EBITDA targets for periods ranging 1-5 years after the acquisition date. The earn-outs are discounted and revaluated on an ongoing basis, based on the current performance and forecasted figures for the acquired companies.

There are currently 25 separate obligations, all with their own targets, capped at a maximum amount. The maximum amount payable if all acquisitions would reach their capped amounts is EUR 152.8 million. A 10 per cent increase in the underlying metric (sales or EBITDA) for all acquisitions compared to the current assumptions would lead to an increase of the contingent consideration of EUR 10.4 million.

Contingent consideration, EURm	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Opening balance	**46.4**	**63.7**	**63.7**
Business combinations	8.4	7.9	8.3
Paid out	-15.0	-32.6	-33.6
Change in fair value recognised in P&L	2.0	2.7	5.5
Probability adjustments recognised in the P&L	0.6	3.0	4.1
Exchange differences on translation of foreign operations	0.6	-1.6	-1.5
Closing balance	**43.0**	**43.1**	**46.4**

Note 6. Business combinations

The following acquisitions have been completed during the period January – June 2026:

EURm	Deal type	Acquired %	Based	Segment	Consolidation month	Annual sales
I-Vet s.r.l.	Share	100%	Italy	Diagnostics	Mar	5.6
Favna ApS	Share	70%	Denmark	Veterinary services	Mar	4.3
VetSave Ltd	Share	100%	Ireland	Veterinary services	May	1.7

I-Vet s.r.l.

On 2 March 2026, the Group acquired 100% of the shares in I-Vet. I-Vet is one of the leading providers to companion animal diagnostics in Italy with annual revenues of around EUR 5.6 million.

Favna ApS

On 5 March 2026, the Group acquired 70% of the shares in Favna, that operates veterinary clinics in Denmark, with annual revenues of around EUR 4.3 million.

VetSave Ltd

On 1 May 2026, the Group acquired 100% of the shares in VetSave. VetSave, with annual revenues of around EUR 1.7 million, provides veterinary practices with buying group services and offers a fully transparent solution to the true cost of veterinary medicines, with all rebates and discounts on the day of purchase.

Preliminary purchase price allocations per operating segment during the period January – June 2026

Acquired net assets on acquisition date based on preliminary PPA, EURm	**Specialty Pharma**	**MedTech**	**Diagnostics**	**Veterinary Services**	**Group total**
Intangible assets			5.7	7.0	12.7
Property, plant and equipment			2.9	0.4	3.3
Right-of-use assets			-	-	-
Non-current financial assets			0.5	0.1	0.6
Deferred tax assets			-	-	-
Inventories			1.2	0.2	1.4
Trade receivable and other receivables			1.8	6.9	8.7
Cash and cash equivalents			0.1	0.4	0.5
Interest-bearing liabilities			-4.1	-	-4.1
Lease liabilities			-	-	-
Deferred tax liabilities			-1.7	-0.9	-2.5
Trade payables and other operating liabilities			-2.2	-8.1	-10.3
Identified net assets			**4.3**	**5.9**	**10.1**
Non-controlling interest measured at fair value			-	-	-
Goodwill			15.3	9.9	25.2
Total purchase consideration			**19.5**	**15.8**	**35.4**
Purchase consideration comprises:					
Cash			14.3	11.6	25.9
Equity instruments			-	-	-
Contingent consideration and deferred payments			5.2	4.2	9.4
Total purchase consideration			**19.5**	**15.8**	**35.4**

Impact of acquisition on Group's cash flow, EURm	**Specialty Pharma**	**MedTech**	**Diagnostics**	**Veterinary Services**	**Group total**
Cash portion of purchase consideration			14.3	11.6	25.9
Acquired cash			-0.1	-0.4	-0.5
Total			**14.2**	**11.2**	**25.4**
Acquisition-related costs			0.9	0.5	1.5
Net cash outflow			**15.1**	**11.8**	**26.9**

The purchase price allocations of I-Vet, Favna and VetSave are deemed preliminary. The group does not expect any material deviations from the current numbers.

Note 7. Related-party transactions

There have been no significant changes in the relationships with related parties for the Group or the Parent Company compared to the information provided in the Annual Financial statements for 2025. All related party transactions are at arm's length.

Year to date an amount of EUR 4.9m in licensing income was invoiced to an entity owned by Nick Bova, manager within the Specialty Pharma segment, that owns Pharmacy licenses as part of regulatory restrictions.

Other related party transactions include rent and fee payments to former owners of acquired businesses. The amounts paid in these transactions are insignificant both individually and as a whole.

Note 8. Events after the balance-sheet date

No significant events occurred after the end of the second quarter.

Note 9. Seasonal effects and risks

Seasonal effects

Vimian assesses that its revenues and EBITA to a limited degree are affected by seasonality. The four segments have varying, but limited, seasonality patterns. The strongest seasonality effect can be seen in MedTech, where the first quarter is typically the strongest quarter due to the AOP programme. During 2024 and 2025 Vimian have reduced the AOP to better align shipments with customer demand for the MedTech segment. As a consequence, the revenue will be more evenly spread throughout the year with limited seasonality for MedTech. For all segments, trading volumes are slightly negatively affected by holiday periods.

Risks and uncertainties

Vimian Group's and the parent company's business risks and risk management, as well as the management of financial risks, are described on pages 64-69 in the 2025 Annual Report published at www.vimian.com.

The group has limited exposure to the current geopolitical environment, mainly being the international supply chain for both finished products and raw materials. In case of tariffs or conflicts this could hurt the groups competitive advantage in certain businesses. To mitigate these risks the group is diversifying its supply chains and implementing contingency plans.

Note 10. Restatement of Statement of profit and loss

As from the fourth quarter 2025, Vimian has changed the accounting of elimination of internal management fees. The elimination was previously netting Other operating income and Other external expenses. The change has no other effect on the financial statements. Comparative periods have been restated accordingly.

EURm	Other operating income		Other external expenses	
	Reported	**Restated**	**Reported**	**Restated**
Jan-mar 2025	-0.1	0.7	-23.1	-23.9
Apr-jun 2025	-0.1	1.0	-20.6	-21.7
Jan-jun 2025	-0.2	1.7	-43.8	-45.7
Jul-sep 2025	-0.1	0.6	-18.0	-18.7
Jan-sep 2025	-0.3	2.3	-61.8	-64.4

ALTERNATIVE PERFORMANCE MEASURES

Alternative Performance Measures (APMs) are financial measures of historical or future financial performance, financial position or cash flows that are not defined in applicable accounting regulations (IFRS). APMs are used by Vimian when it is relevant to monitor and describe Vimian's financial situation and to provide additional useful information to users of financial statements. These measures are not directly comparable to similar key ratios presented by other companies.

Key Ratios	Definition	Reason for usage
Organic Revenue Growth	Change in Revenue in relation to the comparative period adjusted for acquisition and divestment effects and any currency impacts. Acquired businesses are included in Organic growth when they have been part of the Group for 12 months and divested businesses are excluded from Organic growth from the date of divestment in the current and comparative period. The Currency impact is calculated by translating the accounts for year N-1 of subsidiaries having a functional currency different than the currency of the issuer with N exchange rate.	Organic growth is used by investors, analysts and the company's management to monitor the underlying development of revenue between different periods at constant currency and excluding the impact of any acquisitions and/or divestments.
EBIT	Operating profit as reported in the Income statement, i.e. profit for the period excluding finance income, finance costs, share of profit of an associate and income tax expense.	The measure shows the profitability from the operations of the parent company and its subsidiaries.
EBITA	Operating profit excluding amortisation of intangible assets that were originally recognised in connection with business combinations.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company's financing structure.
EBITDA	Operating profit excluding amortisation, depreciation and impairment of intangible and tangible assets.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure.
Adjusted EBITA	EBITA adjusted for items affecting comparability.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation of intangible assets as well as independent of taxes and the Company's financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITA margin	Adjusted EBITA in relation to Revenue.	The measure reflects the business's operating profitability before amortisation of intangible assets. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITDA	EBITDA adjusted for items affecting comparability.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Adjusted EBITDA margin	Adjusted EBITDA in relation to Revenue.	The measure reflects the business's operating profitability before amortisation and depreciation of intangible and tangible fixed assets. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time.
Items affecting comparability	Income and expense items that are considered to be important to specify to users of the financial information since they affect comparability.	A separate disclosure of items affecting comparability is relevant to provide to users of the financial information to give further understanding of the financial performance when comparing of financial performance between periods. Generally accepted NRI's include acquisition and integration related costs, litigation related costs if material, significant restructuring costs (e.g., the consolidation of production footprint in Diagnostics going from four to two production sites), costs related to projects such as the initial public offering.

Key Ratios	Definition	Reason for usage
Amortisation PPA related	Amortisation of intangible assets that were originally recognised in connection with business combinations.	Specification of amortisation in different categories since management differentiates amortisation when calculating EBITA.
Net debt	Cash and cash equivalents less liabilities to credit institutions, lease liabilities, other non-current liabilities and specific items included in other current liabilities (contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations).	Net debt is a measure used to follow the development of debt and the size of the refinancing need. Since cash and cash equivalents can be used to pay off debt at short notice, net debt is used instead of gross debt as a measure of the total loan financing.
Net debt / Adjusted EBITDA (pro-forma)	Net debt in relation to a 12-month period of Adjusted EBITDA (pro-forma).	The measure is a debt ratio that shows how many years it would take to pay off the Company's debt, provided that its net debt and Adjusted EBITDA are constant and without taking into account the cash flows regarding interest, taxes and investments. Net Debt / Adjusted EBITDA is referred to in the report as leverage.
Net Working Capital	Inventory, Trade receivables, Current tax receivables, Other current receivables, Prepaid expenses and Accrued income, less Trade payables, Current tax liabilities, Accrued expenses and deferred income, Provisions and Other current liabilities (excluding contingent considerations, deferred payments, vendor notes and shareholder loans related to business combinations)	Working capital is a measure of the company's short-term financial status
Capex	Total cash flow from investments in tangible and intangible assets during the period. This includes costs for internally developed assets.	Capex is a measure of the company's historical investments and is used as input in calculating Free cash flow and Cash conversion.
Proforma revenue	Reported revenue for the last twelve months plus revenue for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects a fair view of the business's revenue for a full year period.
Adjusted EBITA, Proforma	Reported adjusted EBITA for the last twelve months adding the adjusted EBITA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Adjusted EBITDA, Proforma	Reported adjusted EBITDA for the last twelve months adding the adjusted EBITDA for all acquisitions closed during the last twelve months, as if they had been consolidated the full period.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Adjusted EBITA and EBITDA margin, Proforma	Adjusted proforma EBITA and EBITDA in relation to proforma revenue.	The measure reflects the business's operating profitability and enables comparison of profitability over time, regardless of amortisation and depreciation of intangible and tangible fixed assets as well as independent of taxes and the Company's financing structure. The measure is an important component, together with revenue growth, to follow the Company's value creation. The measure is also adjusted for the impact of items affecting comparability to increase comparability over time. The measure also reflects all closed acquisitions as if they were consolidated for the full period.
Acquisition related expenses	Expenses related to legal and financial due diligence as well as in some cases stay on bonuses to key personnel. If specific initial integration costs are required, and agreed upon during the acquisition process, this can be considered as acquisition related expenses.	
Restructuring costs	Costs relating to significant change of business model or operational structure. Possibly linked to integration between legacy and acquired businesses. The most significant restructuring project to date is the consolidation of production footprint in Diagnostics going from four to two production sites.	

Alternative performance measures not defined in accordance with IFRS for the group - Based on proforma figures

	1 Apr-30 Jun		1 Jan-30 Jun		1 Jan-31 Dec
EURm (unless otherwise stated)	**2026**	**2025**	**2026**	**2025**	**2025**
Revenue growth (%)	17%	15%	12%	16%	13%
Organic revenue growth (%)	12%	5%	10%	5%	6%
Revenue	121.6	104.3	237.6	211.8	425.0
EBITDA	32.8	23.4	64.2	48.0	104.8
EBITDA margin (%)	27.0%	22.4%	27.0%	22.7%	24.7%
Items affecting comparability	-0.9	-5.3	-2.7	-12.3	-14.7
Adjusted EBITDA	33.7	28.7	66.9	60.3	119.5
Adjusted EBITDA margin (%)	27.7%	27.5%	28.2%	28.5%	28.1%
EBITA	28.8	20.0	56.2	41.3	90.7
EBITA margin (%)	23.7%	19.2%	23.7%	19.5%	21.3%
Adjusted EBITA	29.7	25.4	58.9	53.7	105.3
Adjusted EBITA margin (%)	24.5%	24.3%	24.8%	25.3%	24.8%
Operating profit	22.3	14.5	43.5	30.1	66.8
Operating margin (%)	18.4%	13.9%	18.3%	14.2%	15.7%
Capital expenditure	-4.7	-3.0	-11.5	-6.2	-15.1
Cash flow from operating activities	3.8	22.2	26.9	39.3	105.7

	1 Jul - 30 Jun
EURm (unless otherwise stated)	**LTM (2025/2026)**
Proforma revenue	459.1
Adjusted EBITDA, Proforma	128.0
Adjusted EBITDA margin, Proforma	27.9%
Net debt	273.7
Net debt / Adjusted EBITDA, Proforma (x)	2.1x

Reconciliation of alternative performance measures not defined in accordance with IFRS for the group

Certain statements and analyses presented include alternative performance measures (APMs) that are not defined by IFRS. The Company believes that this information, together with comparable defined IFRS metrics, are useful to investors as they provide a basis for measuring operating profit and ability to repay debt and invest in operations. Corporate management uses these financial measurements, along with the most directly comparable financial metrics under IFRS, to evaluate operational results and value added. The APMs should not be assessed in isolation from, or as a substitute for, financial information presented in the financial statements in accordance with IFRS. The APMs reported are not necessarily comparable to similar metrics presented by other companies. The reconciliations are presented in the tables below:

	1 Apr-30 Jun		1 Jan-30 Jun		1 Jan-31 Dec
EURm (unless otherwise stated)	**2026**	**2025**	**2026**	**2025**	**2025**
EBITA/EBITDA and Adjusted EBITA/EBITDA					
Revenue	121.6	104.3	237.6	211.8	425.0
EBIT	22.3	14.5	43.5	30.1	66.8
Amortisation of acquisition related intangibles	6.5	5.6	12.7	11.3	23.8
EBITA	28.8	20.0	56.2	41.3	90.7
Other depreciation	4.0	3.3	8.0	6.7	14.1
EBITDA	32.8	23.4	64.2	48.0	104.8
Items affecting comparability	0.9	5.3	2.7	12.3	14.7
Adjusted EBITA	29.7	25.4	58.9	53.7	105.3
Adjusted EBITDA	33.7	28.7	66.9	60.3	119.5
EBITA margin (%)	**23.7%**	**19.2%**	**23.7%**	**19.5%**	**21.3%**
EBITDA margin (%)	**27.0%**	**22.4%**	**27.0%**	**22.7%**	**24.7%**
Adjusted EBITA margin (%)	**24.5%**	**24.3%**	**24.8%**	**25.3%**	**24.8%**
Adjusted EBITDA margin (%)	**27.7%**	**27.5%**	**28.2%**	**28.5%**	**28.1%**

	30 Jun		31 Dec
EURm (unless otherwise stated)	**2026**	**2025**	**2025**
Net debt			
Liabilities to credit institutions (long term)	261.7	277.5	223.3
Lease liabilities (long term)	11.9	11.8	10.3
Other non-current liabilities	27.3	32.3	20.9
Liabilities to credit institutions (short term)	0.0	-0.2	0.0
Lease liabilities (short term)	5.2	4.7	5.1
Other items[1]	20.2	26.9	42.3
Cash & Cash Equivalents	-51.6	-67.5	-55.0
Other receivables[2]	-1.0	-24.8	-1.5
Net debt	**273.7**	**260.6**	**245.4**

	30 Jun		31 Dec
EURm (unless otherwise stated)	**2026**	**2025**	**2025**
Net working capital			
Inventory	93.4	80.0	80.1
Trade receivables	71.5	58.9	57.3
Current tax receivables	3.1	1.3	1.2
Other current receivables	7.8	8.2	6.7
Prepaid expenses and accrued income	14.4	13.9	13.2
Trade payables	-27.8	-22.8	-20.1
Current tax liabilities	-8.5	-10.4	-10.3
Other current liabilities[3]	-14.2	-8.2	-11.5
Provisions	-2.0	-0.3	-0.8
Accrued expenses and deferred income	-23.5	-21.1	-19.2
Net working capital	**114.1**	**99.5**	**96.6**

[1] Shareholder loans, deferred payments, vendor notes and contingent considerations included in other current liabilities
[2] Other receivables related to the US patent litigation
[3] Other current liabilities as reported in the statement of financial position less shareholder loans, deferred payments, vendor notes and contingent considerations related to business combinations

EURm (unless otherwise stated)	1 Jul - 30 Jun LTM (2025/2026)	1 Jan-31 Dec 2025
Proforma revenue		
Reported revenue	450.9	425.0
Proforma period, revenue	8.2	5.3
Proforma revenue	**459.1**	**430.4**
Adjusted EBITA, Proforma		
Reported Adjusted EBITA (12 months)	110.6	105.4
Proforma period Adjusted EBITA	1.7	3.6
Adjusted EBITA, Proforma	**112.3**	**109.0**
Adjusted EBITA margin, Proforma		
Proforma Revenue	459.1	430.4
Adjusted EBITA, Proforma	112.3	109.0
Adjusted EBITA margin, Proforma	**24.5%**	**25.3%**
Adjusted EBITDA, Proforma		
Reported Adjusted EBITDA (12 months)	126.0	119.5
Proforma period Adjusted EBITDA	2.0	3.7
Adjusted EBITDA, Proforma	**128.0**	**123.1**
Adjusted EBITDA margin, Proforma		
Proforma Revenue	459.1	430.4
Adjusted EBITDA, Proforma	128.0	123.1
Adjusted EBITDA margin, Proforma	**27.9%**	**28.6%**
Net debt/Adjusted EBITDA, Proforma		
Net debt	273.7	245.4
Adjusted EBITDA, Proforma	128.0	123.1
Net debt/Adjusted EBITDA, Proforma (x)	**2.1x**	**2.0x**

Financial calendar

22 October 2026
Interim report Q3 2026
11 February 2027
Year-end report 2026

For further information, please contact

Carl-Johan Zetterberg Boudrie
CFO
carl-johan.zetterberg@vimian.com
+46 703 35 84 49

Maria Dahllöf Tullberg
Head of IR, Communications & ESG
maria.tullberg@vimian.com
+46 736 26 88 86

Vimian Group AB (publ)
Reg. no. 559234-8923
Riddargatan 19
114 57 Stockholm
Sweden
www.vimian.com